| Methods |
Randomized
Multicenter |
| Participants |
Elderly > 70 (mean age: 76)
CAP
Hospitalized |
| Interventions |
Atypical: IV clarythromycin 500 mg + IV ceftriaxone 1 G X 2/d
IV clarythromycin 500 mg + IV amikacin 250 mg X 2/d
versus
Non‐atypical: IV meropenem 500 mg X 3/d
IV imipenem/cilastatin 500 mg X 3/d |
| Outcomes |
Clinical response
Failure = no improvement or deterioration of signs and symptoms OR relapse |
| Notes |
Elderly |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Not described |
| Allocation concealment (selection bias) |
Unclear risk |
Not described |
| Incomplete outcome data (attrition bias)
Mortality |
High risk |
204/226 patients evaluated |
| Incomplete outcome data (attrition bias)
Failure |
High risk |
204/226 patients evaluated |
| Selective reporting (reporting bias) |
Low risk |
Not identified |
| Other bias |
Unclear risk |
Sponsored |
| Blinding of participants and personnel (performance bias)
All outcomes |
High risk |
None |
| Blinding of outcome assessment (detection bias)
All outcomes |
High risk |
None |
